39 related articles for article (PubMed ID: 8656260)
21. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
22. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
23. Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.
Gridelli C; Cigolari S; Maiorino A; Ianniello GP; Brancaccio L; Rossi A; De Cataldis G; Pedicini T; Maiorino L; Barletta E; Di Lanno M; Bilancia D; Crispino C; Barzelloni ML; Masullo P; D'Aniello R; Manzione L
Lung Cancer; 2000 Jun; 28(3):237-44. PubMed ID: 10812192
[TBL] [Abstract][Full Text] [Related]
24. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
25. Amifostine (Ethyol): dosing, administration and patient management guidelines.
Bukowski RM
Eur J Cancer; 1996; 32A Suppl 4():S46-9. PubMed ID: 8976823
[TBL] [Abstract][Full Text] [Related]
26. Platinum organ toxicity and possible prevention in patients with testicular cancer.
Hartmann JT; Kollmannsberger C; Kanz L; Bokemeyer C
Int J Cancer; 1999 Dec; 83(6):866-9. PubMed ID: 10597214
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin-associated neurotoxicity: can it be prevented?
Alberts DS; Noel JK
Anticancer Drugs; 1995 Jun; 6(3):369-83. PubMed ID: 7670134
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin overdose: toxicities and management.
Tsang RY; Al-Fayea T; Au HJ
Drug Saf; 2009; 32(12):1109-22. PubMed ID: 19916578
[TBL] [Abstract][Full Text] [Related]
29. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Schiller JH; Storer B; Berlin J; Wittenkeller J; Larson M; Pharo L; Larson M; Berry W
J Clin Oncol; 1996 Jun; 14(6):1913-21. PubMed ID: 8656260
[TBL] [Abstract][Full Text] [Related]
30. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
31. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
32. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
Duval M; Daniel SJ
J Otolaryngol Head Neck Surg; 2012 Oct; 41(5):309-15. PubMed ID: 23092832
[TBL] [Abstract][Full Text] [Related]
34. A review of the use of chemoprotectants in cancer chemotherapy.
Lewis C
Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
